Construction of Recombinant Vaccinia Viruses Using Leporipoxvirus-Catalyzed Recombination and Reactivation of Orthopoxvirus DNA

  • Xiao-Dan Yao
  • David H. Evans
Part of the Methods in Molecular Biology book series (MIMB, volume 269)


Poxvirus DNA is not infectious because the initiation of the infective process requires proteins encapsidated along with the virus genome. However, infectious virus can be produced if purified poxvirus DNA is transfected into cells previously infected with another poxvirus. This process is termed heterologous reactivation if the infecting virus is different from the transfected virus. We describe a method in which the high-frequency recombination and replication reactions catalyzed by the Leporipoxvirus, Shope fibroma virus (SFV), can be coupled with SFV-promoted reactivation reactions to rapidly construct recombinant vaccinia viruses in high yields (25–100% recombinant progeny). The reactivated vaccinia viruses are easily purified free of the SFV helper virus by plating mixed populations of virus on cells that support only the growth of vaccinia virus. These heterologous reactivation reactions can be used to manipulate the structure of virus genomes and produce viruses that express recombinant proteins at high levels. We illustrate the method by polymerase chain reaction (PCR) cloning the gene encoding green fluorescent protein (GFP), then using double-strand break repair reactions to produce a recombinant virus that expresses high levels of GFP.

Key Words

Genetic recombination green fluorescent protein (GFP) protein expression reactivation Shope fibroma virus (SFV) T7 expression vectors vaccinia virus virus vectors 


  1. 1.
    Yao, X.-D. and Evans, D. H. (2003) High frequency genetic recombination and reactivation of Orthopoxviruses from DNA fragments transfected into Leporipoxvirus-infected cells. J. Virol. 77, 7281–7290.PubMedCrossRefGoogle Scholar
  2. 2.
    Evans, D. H., Stuart, D., and McFadden, G. (1988) High levels of genetic recombination among cotransfected plasmid DNAs in poxvirus-infected mammalian cells. J. Virol. 62, 367–375.PubMedGoogle Scholar
  3. 3.
    Parks, R. J. and Evans, D. H. (1991) Effect of marker distance and orientation on recombinant formation in poxvirus-infected cells. J. Virol. 65, 1263–1272.PubMedGoogle Scholar
  4. 4.
    Yao, X.-D. and Evans, D. H. (2001) Effects of DNA structure and homology length on vaccinia virus recombination. J. Virol. 75, 6923–6932.PubMedCrossRefGoogle Scholar
  5. 5.
    Merchlinsky, M. and Moss, B. (1992) Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors. Virology 190, 522–526.PubMedCrossRefGoogle Scholar
  6. 6.
    Scheiflinger, F., Dorner, F., and Falkner, F. G. (1992) Construction of chimeric vaccinia viruses by molecular cloning and packaging. Proc. Natl. Acad. Sci. USA 89, 9977–9981.PubMedCrossRefGoogle Scholar
  7. 7.
    Sam, C. K. and Dumbell, K. R. (1981) Expression of poxvirus DNA in coinfected cells and marker rescue of thermosensitive mutants by subgenomic fragments of DNA. Ann. Virol. (Inst. Past.) 132, 135–150.CrossRefGoogle Scholar
  8. 8.
    Fuerst, T. R., Earl, P. L., and Moss, B. (1987) Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol. Cell Biol. 7, 2538–2544.PubMedGoogle Scholar
  9. 9.
    Earl, P. L., Moss, B., Wyatt, L. S., and Carroll, M. W. (1998) Generation of recombinant vaccinia viruses in Current Protocols in Molecular Biology (Ausubel, F. M., ed.), John Wiley and Sons, Brooklyn, NY, pp. 16.17.1–16.17.19.Google Scholar
  10. 10.
    Elroy-Stein, O., Fuerst, T. R., and Moss, B. (1989) Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5′ sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc. Natl. Acad. Sci. USA 86, 6126–6130.PubMedCrossRefGoogle Scholar
  11. 11.
    Moss, B., Elroy-Stein, O., Mizukami, T., Alexander, W. A., and Fuerst, T. R. (1990) Product review. New mammalian expression vectors. Nature 348, 91–92.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2004

Authors and Affiliations

  • Xiao-Dan Yao
    • 1
  • David H. Evans
    • 1
    • 2
  1. 1.Department of Molecular Biology & GeneticsUniversity of GuelphGuelphCanada
  2. 2.Department of Medical Microbiology & ImmunologyUniversity of AlbertaEdmontonCanada

Personalised recommendations